SA PRO
Free Account
Editas Medicine, Inc.EDITNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
22 analysts·High coverage
55%
Rating Distribution
Strong Buy
00%
Buy
1255%
Hold
836%
Sell
29%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 524% higher.

Bear Case
$5.00
+143%
Consensus
$12.85
+524%
Bull Case
$35.00
+1599%
Price Range22 analysts
Low
Consensus
High
$5.00
$35.00
Current Target
Current Price
$2.06
Upside to Target
$10.79

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 5, 2024Barclays
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
Target:$5.00
+60.3%from $3.12
Oct 23, 2024Wells Fargo
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo
Target:$9.00
+173.6%from $3.29
Oct 22, 2024Robert W. Baird
Editas Medicine (EDIT) PT Lowered to $10 at Baird
Target:$10.00
+204.0%from $3.29
Aug 8, 2024Truist Financial
Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities
Target:$12.00
+183.0%from $4.24
Aug 8, 2024Bank of America Securities
BofA Securities Upgrades Editas Medicine (EDIT) to Buy
Target:$15.00
+256.7%from $4.21
May 30, 2024Evercore ISI
Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI
Target:$7.00
+37.3%from $5.10
May 9, 2024Morgan Stanley
Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight
Target:$7.00
+39.0%from $5.04
Sep 28, 2023Stifel Nicolaus
Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation'
Target:$17.00
+145.7%from $6.92
Dec 13, 2022Citigroup
Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11
Target:$11.00
+10.4%from $9.96
Nov 18, 2022Morgan Stanley
Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $8
Target:$8.00
-24.8%from $10.63
Nov 18, 2022RBC Capital
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $14
Target:$14.00
+27.2%from $11.01
Nov 18, 2022Truist Financial
Editas Medicine price target lowered to $35 from $80 at Truist
Target:$35.00
+217.9%from $11.01
Nov 18, 2022Oppenheimer
Oppenheimer Downgrades Editas Medicine to Perform, Lowers Price Target to $12
Target:$12.00
+9.0%from $11.01
Nov 18, 2022Credit Suisse
Credit Suisse Downgrades Editas Medicine to Neutral, Lowers Price Target to $13
Target:$13.00
+18.1%from $11.01
Nov 18, 2022Chardan Capital
Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $35
Target:$35.00
+217.9%from $11.01
Jan 6, 2022Morgan Stanley
Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT)
Target:$24.00
-1.7%from $24.41
Nov 8, 2021Robert W. Baird
Analyst Action
Target:$44.00
+8.5%from $40.57
Sep 29, 2021Truist Financial
Editas' EDIT-101 topped bar seen by experts as FDA hurdle, says Truist
Target:$80.00
+88.2%from $42.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance